




我找的是 SIR-Sphere，他的適應症是肝癌的移轉，之所以找他是因為健喬(4114)是他的製造商，此藥於2011 年的第二季取得藥證，初期走的是自費市場，預計半年以後會取得健保藥價給付，這產品在公司裡面算是一個 star，預計與另外兩個新取得藥證 INNO-Mustin、HepaShere 的抗癌藥在 2012 可以貢獻公司營收 1-1.2 億元(參考資料：公開資訊觀測站、投顧)

Thomson Innovation - Windows Internet Explorer
http://www.thomsoninnovation.com/tip-innovation/recordView.do?pager.offset=0&recordCount=1&parentIds=null&totalRecords=5&fromRecordView=false&datasource

Patent Record View - US7723023B2 [Close Record View](#)

Record View: Patent US7723023B2 [? Help](#)

[Add to Work File](#) | [Mark Record](#) | [Watch Record](#) | [Download](#) | [Print](#)

Quick View [Go to Full View](#)

DWPI Title ?
New solid substrate comprising several polymers or 50-1000 different nucleic acids coupled to the solid substrate in a different known location, useful for high content drug profiling and toxicity screening


Original Title ?
Use of intrinsic reporters of cell signaling for high content drug profiling and toxicity screening

Abstract ?
The present invention identifies essentially all of the members of a specific group of genes that are preferentially transcribed upon the initialization of a signal transduction pathway. The present invention also discloses methods for detecting and/or quantifying the transcription of these specific genes. The present invention further discloses methods of using this information to characterize the effect of potential drugs on a cell. Solid supports comprising nucleic acids that can hybridize with the transcripts from this specific group of genes are also described.

First Claim ?
1. A method of evaluating and/or predicting whether a candidate compound has a beneficial therapeutic receptor active drug activity or a hallucinogenic or toxic side-effect as compared to a group of reference compounds that have known beneficial

Record 1 of 5

Images
Image 1/17 [Zoom \(+\)](#)



[Mark and Next](#)

完成 網路網路 | 受保護模式: 關閉 100% 下午 04:02 2011/12/28

這是專利檢所的部分，這次我查的是 Lasyn，一樣是健喬的代工產品，他是專門用來降血脂肪的！

由於預計 2011 年 E P S = -0.22 元，虧損原因雖為轉投資公司的虧損，但就算拿 2012EPS=0.89 來計算，今 (28) 本益比高達 30 倍！故目前價格不建議購買。